慢阻肺经常发作可以用罗氟司特吗？需要满足什么情况才能用罗氟司特？

Can roflumilast be used if COPD has frequent attacks? What conditions need to be met before using roflumilast? On March 1, 2011, the U.S. Food and Drug Administration (FDA) approved Roflumilast, formerly known as Daxas, for the treatment of frequent exacerbations (exacerbations) or worsening of symptoms of severe chronic obstructive pulmonary disease (COPD). COPD is a severe lung disease that can cause difficulty breathing. The main symptoms include wheezing, chronic cough, and excessive phlegm. An attack can last for several weeks and can lead to reduced lung function, severe anxiety, and even an increased risk of death. It is a new class of drugs for the treatment of COPD and is a phosphodiesterase type 4 (PDE4) inhibitor. The drug is indicated for treating cough and phlegm caused by bronchitis in patients with severe COPD, but not for another type of COPD, primary emphysema.

The drug can specifically act on a certain enzyme involved in smooth muscle contraction, prevent the degradation of cAMP, thereby blocking the transmission of pro-inflammatory response signals. It has anti-inflammatory activity and has achieved good results in the clinical treatment of asthma and chronic obstructive pulmonary disease. Roflumilast can also significantly delay the worsening of respiratory symptoms and greatly improve the patient's quality of life.

Roflumilast is a once-daily oral tablet that must be combined with other bronchodilators. It is suitable for adult patients with chronic bronchitis and related severe COPD with a history of frequent exacerbations, and can be used as maintenance treatment. FDA-approved dosing information for roflumilast shows potential mental health risks, including changes in mood, thinking, or behavior, and unexplained weight loss. Roflumilast is not expected to be used in the treatment of other symptoms of COPD, including emphysema. Roflumilast should not be used to treat sudden breathing problems (acute bronchospasm) and is not recommended for patients under 18 years of age. The main adverse reactions reported include: diarrhea, nausea, headache, insomnia, back pain, decreased appetite and dizziness.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.